"Androstadienes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivatives of the steroid androstane having two double bonds at any site in any of the rings.
Descriptor ID |
D000730
|
MeSH Number(s) |
D04.210.500.054.079.129
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Androstadienes".
Below are MeSH descriptors whose meaning is more specific than "Androstadienes".
This graph shows the total number of publications written about "Androstadienes" by people in this website by year, and whether "Androstadienes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 1 | 2 |
1996 | 0 | 1 | 1 |
1999 | 0 | 1 | 1 |
2000 | 1 | 2 | 3 |
2001 | 1 | 8 | 9 |
2002 | 2 | 4 | 6 |
2003 | 2 | 6 | 8 |
2004 | 5 | 3 | 8 |
2005 | 2 | 2 | 4 |
2006 | 0 | 1 | 1 |
2007 | 1 | 1 | 2 |
2008 | 3 | 4 | 7 |
2010 | 2 | 1 | 3 |
2011 | 6 | 2 | 8 |
2012 | 6 | 6 | 12 |
2013 | 5 | 1 | 6 |
2014 | 6 | 1 | 7 |
2015 | 1 | 2 | 3 |
2016 | 0 | 1 | 1 |
2017 | 5 | 4 | 9 |
2018 | 1 | 2 | 3 |
2019 | 1 | 2 | 3 |
2020 | 5 | 1 | 6 |
2021 | 1 | 3 | 4 |
2022 | 0 | 1 | 1 |
2023 | 0 | 1 | 1 |
2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Androstadienes" by people in Profiles.
-
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer. JAMA Oncol. 2024 Oct 01; 10(10):1379-1389.
-
Characterization of Moderate and Severe Asthma Exacerbations in the CAPTAIN Study. J Allergy Clin Immunol Pract. 2024 Sep; 12(9):2372-2380.e5.
-
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nat Commun. 2024 Mar 19; 15(1):2446.
-
COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA. Int J Chron Obstruct Pulmon Dis. 2023; 18:407-418.
-
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis. Respir Med. 2022 12; 205:107040.
-
Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials. Int J Chron Obstruct Pulmon Dis. 2021; 16:1925-1938.
-
Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer. Clin Pharmacol Ther. 2021 10; 110(4):1038-1049.
-
Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT. Ann Am Thorac Soc. 2021 05; 18(5):788-798.
-
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer. Clin Cancer Res. 2021 06 15; 27(12):3329-3338.
-
Reply to L?pez-Campos et al.: Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect. Am J Respir Crit Care Med. 2021 04 01; 203(7):928-929.